From the CEO update 9 July 2018 ...
On 1 June 2018 we held the first formal review of our platform with our newly appointed Scientific Advisory Board. It was clear from this discussion that Phylogica has a near-term opportunity to improve the commercial attractiveness of our platform by showing that we can deliver a cargo class of interest into a target cell of interest more efficiently than the relevant competitive technology.
This sounds to me like the Advisory Board saying “you are on the right path so demonstrate it, build your data pack and get ahead of your competition.
My initial thoughts were that they have dumped a tough target (MYC) to tackle a tougher target. However, I now understand and accept the reasoning behind the MYC decision and I sense that the next step (demonstrate it) will be a massive moment for the company. Gee I hope so.
From the CEO update 9 July 2018 ... On 1 June 2018 we held the...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
